title: Treating to target in axial spondyloarthritis: defining the target and the arrow.
abstract: The treat-to-target concept is currently proposed in axial spondyloarthritis and aims for remission to be reached and maintained. Consensual definitions of remission and flare of the disease are currently lacking but are needed to validate this strategy and to confirm the window of opportunity hypothesis. The discovery of new therapeutic targets, such as IL-23 and IL-17, will enable and enlarge the possibility of targeted therapies in axial spondyloarthritis.
authors.affiliation: Department of Rheumatology, CHRU de Besançon, University Teaching Hospital, and Université de Franche-Comté, Boulevard Fleming, F-25030, Besançon, France.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D020381:Interleukin-17 / Q000276:immunology*; D053759:Interleukin-23 / Q000276:immunology*; D058990:Molecular Targeted Therapy; D012074:Remission Induction; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D020381:Interleukin-17; D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha
keywords: IL 17; IL 23; ankylosing spondylitis; remission; spondyloarthritis; treatment